MAINZ BIOMED N.V. Ordinary Shares (par value €0.01 per share) Controlled Equity OfferingSM Sales AgreementSales Agreement • December 30th, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
Mainz Biomed N.V., a Dutch public limited liability company (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
PLACEMENT AGENCY AGREEMENT November 13, 2023Placement Agency Agreement • November 15th, 2023 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
Introduction. Subject to the terms and conditions herein (this “Agreement”), Mainz Biomed N.V., a public company under Dutch law (the “Company”), hereby agrees to sell up to an aggregate of $5,000,000.40 of securities of the Company, including, but not limited to, ordinary shares (the “Shares” or “Securities”) of the Company, €0.01 par value per Share (the “Ordinary Shares”) and warrants (the “Warrants”) to purchase Ordinary Shares (the “Warrant Shares” and, together with the Shares and the Warrants, the “Securities”) directly to various investors (each, an “Investor” and, collectively, the “Investors”) through Titan Partners Group LLC, a division of American Capital Partners, LLC (together with its affiliates, “Titan Partners” or the “Placement Agent”) as placement agent. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, securities purchase agreements (the “Purchase Agreements”), sha
Securities PURCHASE AGREEMENTSecurities Purchase Agreement • November 15th, 2023 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 13, 2023, between Mainz Biomed N.V., a public company under Dutch law (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
Mainz Biomed N.V. UNDERWRITING AGREEMENTUnderwriting Agreement • January 28th, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between Mainz Biomed N.V., a Dutch public company with limited liability (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereafter defined) as being subsidiaries or affiliates of the Company, the “Company”) on the one hand, and Boustead Securities, LLC (the “Underwriter”), on the other hand, pursuant to which the Underwriter shall serve as the underwriter for the Company in connection with the proposed offering (the “Offering”) by the Company of their Securities (as defined below) on a “Firm Commitment” basis.
Mainz Biomed N.V. UNDERWRITING AGREEMENTUnderwriting Agreement • January 21st, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between Mainz Biomed N.V., a Dutch public company with limited liability (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereafter defined) as being subsidiaries or affiliates of the Company, the “Company”) on the one hand, and Boustead Securities, LLC (the “Underwriter”), on the other hand, pursuant to which the Underwriter shall serve as the underwriter for the Company in connection with the proposed offering (the “Offering”) by the Company of their Securities (as defined below) on a “Firm Commitment” basis.
Mainz Biomed B.V. UNDERWRITING AGREEMENTUnderwriting Agreement • November 12th, 2021 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This underwriting agreement (this “Agreement”) constitutes the agreement between Mainz Biomed B.V., a Dutch company limited by shares (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereafter defined) as being subsidiaries or affiliates of the Company, the “Company”) on the one hand, and Boustead Securities, LLC (the “Underwriter”), on the other hand, pursuant to which the Underwriter shall serve as the underwriter for the Company in connection with the proposed offering (the “Offering”) by the Company of their Securities (as defined below) on a “Firm Commitment” basis.
DATED 29 JULY 2021 CONTRIBUTION AGREEMENTContribution Agreement • October 12th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • May 3rd, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • California
This Employment Agreement (the “Agreement”) is made and entered into as of April 29, 2022 (effective May 1, 2022), by and between William J. Caragol (the “Employee”) and Mainz Biomed N.V. (the “Company”).
Silent Partnership Agreement Between the Company PharmGenomics GmbH, Robert- Koch-Str. 50, 55129 Mainz, Germany - hereinafter also referred to as the “Participant” - and the - hereinafter also referred to as the “Participation Provider” - OverviewPartnership Agreement • October 12th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
Intellectual Property Asset Purchase AgreementIntellectual Property Asset Purchase Agreement • February 21st, 2023 • Mainz Biomed N.V. • Pharmaceutical preparations
BETWEEN: MAINZ BIOMED N.V., a corporate body incorporated in Amsterdam, with its principal place of business located at Sirius Gutenberg Park Robert-Koch-Straße 50, 55129, Mainz, Germany;
AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • October 26th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion to a Naamloze Venootschap under Dutch law, the “Company”) and Dr. Moritz Eidens (“Eidens”).
CONSULTANT AGREEMENTConsultant Agreement • August 3rd, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations • New York
This Consultant Agreement (the “Agreement”) is made and entered into as of July 16, 2021, by and between William Caragol (the “Consultant”) and Mainz Biomed B.V. (the “Company”).
AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • October 26th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion to a Naamloze Venootschap under Dutch law, the “Company”) and Philipp Freese (“Freese”).
AMENDMENT NO. 1 TO CONSULTANT AGREEMENTConsultant Agreement • October 26th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO CONSULTANT AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion to a Naamloze Venootschap under Dutch law, the “Company”) and William Caragol (the “Consultant”).
Amendment to License AND DEVELOPMENT agreementLicense and Development Agreement • August 3rd, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
This amendment refers to the License and Development Agreement entered into the 1st of January, 2019 (the ”Agreement”) between the parties:
SUPPLEMENTAL AGREEMENTSupplemental Agreement • April 19th, 2024 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
This Supplemental Agreement (the “Agreement”), dated as of April ___, 2024, is entered into by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”) and MAINZ BIOMED N.V., a company incorporated under the laws of the Netherlands and registered with the trade register of the Chamber of Commerce under number 82122571 (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.”
PRE-PAID ADVANCE AGREEMENTAdvance Agreement • June 28th, 2023 • Mainz Biomed N.V. • Pharmaceutical preparations • New York
THIS PRE-PAID ADVANCE AGREEMENT (this “Agreement”) dated as of June 28, 2023 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and MAINZ BIOMED N.V., a company incorporated under the laws of the Netherlands and registered with the trade register of the Chamber of Commerce under number 82122571 (the “Company”). The Investor and the Company may be referred to herein individually as a “Party” and collectively as the “Parties.”
AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • October 26th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MANAGEMENT SERVICES AGREEMENT (this “Amendment”), dated as of October ___, 2021, by and among MAINZ BIOMED B.V. (including upon conversion to a Naamloze Venootschap under Dutch law, the “Company”) and Guido Bächler (“Baechler”).
Assignment AgreementAssignment Agreement • February 21st, 2023 • Mainz Biomed N.V. • Pharmaceutical preparations • Quebec
BETWEEN: SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C., operating under the name TRANSFERTECH SHERBROOKE, a Limited Partnership duly incorporated pursuant to the Civil Code of Québec, having its head office at 35 Radisson Street, Office 200, Sherbrooke, (Quebec), Canada, J1L 1E2, acting and represented by its General Partner, GESTION SOCPRA SCIENCES SANTÉ ET HUMAINES INC., a legal person duly constituted under the Business Corporations Act (Quebec), said General Partner being represented by its agent and mandatory GESTION SOCPRA INC, herein acting and represented by Michel Lambert, its President and CEO, duly authorized for the purposes hereof as he so declares by signing;
TECHNOLOGY RIGHTS AGREEMENTTechnology Rights Agreement • January 21st, 2022 • Mainz Biomed N.V. • Pharmaceutical preparations • Quebec
BETWEEN: Socpra sciences santé et humaines s.e.c., operating under the name TransferTech Sherbrooke, a Limited Partnership duly incorporated pursuant to the Civil Code of Québec, having its head office at 35 Radisson Street, Office 200, Sherbrooke, (Quebec), Canada, J1L 1E2, acting and represented by its General Partner, Gestion Socpra sciences santé et humaines inc., a legal person duly constituted under the Business Corporations Act (Quebec), said General Partner being represented by its agent and mandatory Gestion socpra Inc, herein acting and represented by Michel Lambert, its President and CEO, duly authorized for the purposes hereof as he so declares by signing; hereinafter referred to as “TTS”
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • October 12th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations • California
This Management Services Agreement (the “Agreement”) is made and entered into as of July 1, 2021 by and between Guido Bächler (“Baechler”) and Mainz Biomed B.V. (the “Company”).
LICENSE and DEVELOPMENT AGREEMENT between ColoAlert AS and PharmGenomics GmbHLicense and Development Agreement • October 12th, 2021 • Mainz Biomed B.V. • Pharmaceutical preparations
